FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

         (Mark One)
             X            Quarterly Report Pursuant to Section 13 or 15(d)
                              of the Securities Exchange Act of 1934

                                For Quarter Ended: November 30, 2001
                                                OR
             _           Transition Report Pursuant to Section 13 or 15(d)
                              of the Securities Exchange Act of 1934

                                   Commission File Number: 0-14820

                                           IMMUCOR, INC.
                       (Exact name of registrant as specified in its charter)


                           Georgia                          22-2408354
                  (State or other jurisdiction of        (I.R.S. Employer
                  incorporation or organization)        Identification No.)

                3130 Gateway Drive P.O. Box 5625 Norcross, Georgia 30091-5625
               (Address of principal executive offices)            (Zip Code)


                       Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                    Yes X No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

       As of December 31, 2001: Common Stock, $0.10 Par Value - 7,277,617


<PAGE>



<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                           CONSOLIDATED BALANCE SHEETS
---------------------------------------------------------------------------------------------------------------------------------


                                                                                        November 30, 2001       May 31, 2001
                                                                                      -------------------------------------------
ASSETS                                                                                    (Unaudited)             (Audited)

CURRENT ASSETS:
<S>                                                                                            <C>                   <C>
   Cash and cash equivalents                                                                   $ 3,550,985           $ 3,124,517
   Accounts receivable, trade - Net                                                             24,886,156            21,167,490
   Loan to officer                                                                                 250,826               395,826
   Inventories                                                                                  15,079,954            15,668,637
   Income taxes receivable                                                                         553,717               402,243
   Deferred income taxes                                                                           578,015               631,797
   Prepaid expenses and other                                                                    2,339,524               891,356
                                                                                      ---------------------  --------------------

     Total current assets                                                                       47,239,177            42,281,866

LONG-TERM INVESTMENT - At cost                                                                   1,000,000             1,000,000

PROPERTY, PLANT AND EQUIPMENT - Net                                                             17,492,357            18,333,952

DEFERRED INCOME TAXES                                                                            1,525,936             1,525,936

OTHER ASSETS - Net                                                                               2,202,444             2,104,845

DEFERRED LICENSING COSTS - Net                                                                   1,499,474             1,652,102

EXCESS OF COST OVER NET TANGIBLE ASSETS ACQUIRED - Net                                          28,278,333            28,913,981
                                                                                      ---------------------  --------------------

                                                                                               $99,237,721           $95,812,682
                                                                                      =====================  ====================

</TABLE>
















See notes to consolidated financial statements.


<PAGE>

<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                     CONSOLIDATED BALANCE SHEETS (continued)
----------------------------------------------------------------------------------------------------------------------------------


                                                                                        November 30, 2001       May 31, 2001
                                                                                      --------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY                                                       (Unaudited)             (Audited)

CURRENT LIABILITIES:
<S>                                                                                       <C>                     <C>
   Current portion of borrowings under bank line of credit agreements                     $    2,466,061          $    2,417,121
   Current portion of long-term debt                                                           4,160,746               5,563,363
   Note payable to related party                                                                 177,563                 349,654
   Current portion of capital lease obligations                                                  773,963                 768,142
   Accounts payable                                                                           10,100,529               8,647,066
   Income taxes payable                                                                          594,657                  23,102
   Accrued salaries and wages                                                                  1,066,360               1,530,772
   Deferred income taxes                                                                         382,116                  98,308
   Other accrued liabilities                                                                   5,676,740               3,561,676
                                                                                      ----------------------  --------------------

     Total current liabilities                                                                25,398,735              22,959,204

BORROWINGS UNDER BANK LINE OF CREDIT AGREEMENTS                                                2,752,379               3,268,740
LONG-TERM DEBT                                                                                32,809,352              34,839,576
CAPITAL LEASE OBLIGATIONS                                                                      1,262,652               1,629,705

DEFERRED INCOME TAXES                                                                          2,813,337               3,119,402

OTHER LIABILITIES                                                                                182,511                 152,588

SHAREHOLDERS' EQUITY:
   Common stock - authorized 45,000,000 shares, $0.10 par value; 7,277,617 issued
     and outstanding                                                                             727,762                 727,762
   Additional paid-in capital                                                                 15,439,889              15,439,889
   Retained earnings                                                                          23,745,444              20,261,628
   Accumulated other comprehensive loss                                                       (5,894,340)             (6,585,812)
                                                                                      ----------------------  --------------------

     Total shareholders' equity                                                               34,018,755              29,843,467
                                                                                      ----------------------  --------------------

                                                                                           $  99,237,721           $  95,812,682
                                                                                      ======================  ====================

</TABLE>










See notes to consolidated financial statements.



<PAGE>

<TABLE>
<CAPTION>

                                                    IMMUCOR, INC.
                                       CONSOLIDATED STATEMENTS OF OPERATIONS
                                                    (Unaudited)
                                                                Three Months Ended                  Six Months Ended
                                                         November 30,     November 30,      November 30,     November 30,
                                                             2001             2000              2001             2000

<S>                                                     <C>              <C>               <C>              <C>
NET SALES.............................................  $   20,918,272   $   16,813,264    $   39,558,234   $   33,894,506

COST OF SALES.........................................       9,093,201        8,839,249        18,470,710       17,407,203
                                                        --------------  ---------------    --------------   --------------
GROSS MARGIN..........................................      11,825,071        7,974,015        21,087,524       16,487,303
                                                        --------------  ---------------    --------------   --------------
OPERATING EXPENSES:
     Research and development.........................         492,692          528,329           979,704        1,001,354
     Selling and marketing............................       2,825,111        3,065,417         5,304,720        6,246,879
     Distribution.....................................       1,457,027        1,411,523         2,890,735        2,839,124
     General and administrative.......................       2,895,100        2,131,915         5,394,019        4,501,825
     Amortization expense.............................         406,705          443,661           814,516          927,753
                                                        --------------  ---------------    --------------   --------------
        Total operating expenses......................       8,076,635        7,580,845        15,383,694       15,516,935
                                                        --------------  ---------------    --------------   --------------
INCOME FROM OPERATIONS................................       3,748,436          393,170         5,703,830          970,368
                                                        --------------  ---------------    --------------   --------------
OTHER INCOME (EXPENSE):
     Interest income..................................           2,600           17,238             3,668           21,025
     Interest expense.................................      (1,427,519)        (814,026)       (2,579,937)      (1,679,741)
     Other - net......................................         499,606           41,645         1,172,186          126,946
                                                        --------------  ---------------    --------------   --------------
        Total other...................................        (925,313)        (755,143)       (1,404,083)      (1,531,770)
                                                        --------------  ---------------    --------------   --------------
INCOME (LOSS) BEFORE INCOME TAXES.....................       2,823,123         (361,973)        4,299,747         (561,402)
INCOME TAX EXPENSE....................................         591,983          250,276           815,931          266,278
                                                        --------------  ---------------    --------------   --------------
NET INCOME (LOSS).....................................  $    2,231,140   $     (612,249)   $    3,483,816   $     (827,680)
                                                        ==============   ==============    ==============   ==============
Earnings (loss) per share:
     Basic............................................       $0.31           $(0.08)            $0.48           $(0.11)
                                                        ==============   ==============   ==============    ==============
     Diluted..........................................       $0.30           $(0.08)            $0.48           $(0.11)
                                                        ==============   ==============   ==============    ==============

Weighted average shares outstanding:
     Basic............................................     7,277,617        7,277,617         7,277,617        7,294,709
                                                        ==============   ==============   ==============    ==============
     Diluted..........................................     7,350,040        7,277,617         7,323,136        7,294,709
                                                        ==============   ==============   ==============    ==============
</TABLE>






See notes to consolidated financial statements.


<PAGE>




<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)
-----------------------------------------------------------------------------------------------------------------------------
                                                                                                  Six Months Ended
                                                                                           November 30,      November 30,
                                                                                               2001              2000
                                                                                         ------------------------------------
OPERATING ACTIVITIES:
<S>                                                                                          <C>                 <C>
   Net income (loss)                                                                         $3,483,816          $(827,680)
   Adjustments to reconcile net income (loss)  to net cash provided by (used in)
     operating activities:
     Depreciation and amortization of property and equipment                                  2,290,983          1,551,760
     Amortization of other assets and excess of cost over net tangible assets acquired          814,516            927,753
     Changes in operating assets and liabilities:
       Accounts receivable, trade                                                            (3,304,171)           514,034
       Loan payment from officer                                                                145,000                  -
       Income taxes                                                                             451,607           (380,472)
       Inventories                                                                              588,683         (2,108,262)
       Other current assets                                                                  (1,400,590)          (988,141)
       Accounts payable                                                                       1,453,463            805,772
       Other current liabilities                                                              1,680,575            (10,127)
                                                                                         -----------------  -----------------

         Total adjustments                                                                    2,720,066            312,317
                                                                                         -----------------  -----------------

Cash provided by (used in) operating activities                                               6,203,882           (515,363)

INVESTING ACTIVITIES:
   Purchases of / deposits on property and equipment                                         (1,820,441)        (1,189,018)
   Decrease in other assets                                                                           -              6,905
                                                                                         -----------------  -----------------

Cash used in investing activities                                                            (1,820,441)        (1,182,113)

FINANCING ACTIVITIES:
   Borrowings under line of credit agreements net of repayments                                (669,274)         2,640,148
   Proceeds from issuance of long term debt and capital lease obligations                             -          3,191,572
   Repayment of long-term debt and capital lease obligations                                 (4,098,151)        (2,398,030)
   Repayment of notes payable                                                                  (172,091)                 -
   Purchase and retirement of stock (184,500 shares)                                                  -         (1,484,713)
                                                                                         -----------------  ----------------

Cash (used in) provided by financing activities                                              (4,939,516)         1,948,977

EFFECT OF EXCHANGE RATE CHANGES ON CASH                                                         982,543           (562,389)
                                                                                         -----------------  ----------------

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                                                426,468           (310,888)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                              3,124,517          3,505,926
                                                                                         -----------------  ----------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                                                   $3,550,985         $3,195,038
                                                                                         =================  ================
</TABLE>


See notes to consolidated financial statements


<PAGE>


                                  IMMUCOR, INC.
                   Notes to Consolidated Financial Statements
                                   (Unaudited)

1.       Basis of Presentation

The accompanying  unaudited consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States
for interim financial  information and the instructions to Form 10-Q and Article
10 of Regulation  S-X.  Accordingly,  they do not include all of the information
and footnotes required by accounting principles generally accepted in the United
States for complete financial  statements.  However,  there has been no material
change in the information disclosed in the Company's annual financial statements
dated May 31, 2001,  except as disclosed  herein.  In the opinion of management,
all adjustments  (consisting of normal recurring accruals)  considered necessary
for a fair presentation have been included.  Operating results for the six-month
period ended  November 30, 2001 are not  necessarily  indicative  of the results
that may be expected for the year ending May 31, 2002. For further  information,
refer to the consolidated financial statements and footnotes thereto included in
the Company's Annual Report on Form 10-K for the year ended May 31, 2001.


2.       INVENTORIES

Inventories are stated at the lower of first-in, first-out cost or market:

                                      As of                     As of
                               November 30, 2001           May 31, 2001
                             ----------------------    ----------------------
Raw materials and supplies             $ 4,795,429               $ 5,524,301
Work in process                          1,979,319                 2,095,363
Finished goods                           8,305,206                 8,048,973
                             ----------------------    ----------------------
                                       $15,079,954               $15,668,637
                             ======================    ======================

3.    EARNINGS (LOSS) PER SHARE

The following table sets forth the computation of basic and diluted earnings per
share in accordance  with Statement of Financial  Accounting  Standards No. 128,
Earnings per Share.
<TABLE>
<CAPTION>

                                                         Three Months Ended                 Six Months Ended
                                                    November 30,     November 30,     November 30,     November 30,
                                                        2001             2000             2001             2000
                                                   ---------------- ---------------  ---------------- ---------------
Numerator for basic and diluted earnings
(loss) per share:
<S>                                                     <C>             <C>               <C>             <C>
Income (loss) available to common shareholders          $2,231,140      $(612,249)        $3,483,816      $(827,680)
                                                   ================ ===============  ================ ===============
Denominator:
  For basic earnings (loss) per share - weighted
      average basis                                      7,277,617       7,277,617         7,277,617       7,294,709
  Effect of dilutive stock options and warrants             72,423               -            45,519               -
                                                   ---------------- ---------------  ---------------- ---------------
  Denominator for diluted earnings (loss) per
     share-adjusted weighted-average shares              7,350,040       7,277,617         7,323,136       7,294,709
                                                   ================ ===============  ================ ===============

Basic earnings (loss) per share                              $0.31         $(0.08)             $0.48         $(0.11)
                                                   ================ ===============  ================ ===============

Diluted earnings (loss) per share                            $0.30         $(0.08)             $0.48         $(0.11)
                                                   ================ ===============  ================ ===============
</TABLE>



<PAGE>



4.    DOMESTIC AND FOREIGN OPERATIONS

Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):
<TABLE>
<CAPTION>

                               ---------------------------------------------------------------------------------------------------
                                                              Three Months Ended November 30, 2001
                               ---------------------------------------------------------------------------------------------------
                                 U.S.         Germany       Italy         Canada        Other       Eliminations     Consolidated
Net sales:
<S>                             <C>            <C>           <C>           <C>           <C>        <C>               <C>
   Unaffiliated customers       $14,352        $2,475        $1,586        $1,259        $1,246     $      -          $20,918
   Affiliates                     1,725           263             -            15            23       (2,049)               -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------
      Total                      16,077         2,738         1,586         1,274         1,269       (2,049)          20,918

Income (loss)from operations      3,454            93           162           299          (260)           -            3,748



                               ---------------------------------------------------------------------------------------------------
                                                               Three Months Ended November, 2000
                               ---------------------------------------------------------------------------------------------------
                                 U.S.         Germany       Italy         Canada        Other       Eliminations     Consolidated
Net sales:
   Unaffiliated customers       $10,532        $2,090        $1,330        $1,520        $1,341     $      -           $16,813

   Affiliates                     1,778            76             -            26            53       (1,933)               -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------
      Total                      12,310         2,166         1,330         1,546         1,394       (1,933)          16,813

Income (loss) from operations        39           282           117           361          (347)         (59)             393


                               ---------------------------------------------------------------------------------------------------
                                                               Six Months Ended November 30, 2001
                               ---------------------------------------------------------------------------------------------------

                                 U.S.         Germany       Italy         Canada        Other       Eliminations     Consolidated
Net sales:
   Unaffiliated customers       $26,820        $4,685        $3,010        $2,556        $2,487     $      -          $39,558
   Affiliates                     3,584           618             -            47           150       (4,349)               -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------
      Total                      30,404         5,303         3,010         2,603         2,637       (4,349)          39,558

Income (loss)from  operations     4,589           295           283           645           (85)         (23)           5,703


                               ---------------------------------------------------------------------------------------------------
                                                               Six Months Ended November 30, 2000
                               ---------------------------------------------------------------------------------------------------

                                 U.S.         Germany       Italy         Canada        Other       Eliminations     Consolidated
Net sales:
   Unaffiliated customers       $21,192        $4,122        $2,744        $2,761        $3,076     $       -         $33,895

   Affiliates                     3,387           147             -            45            89       (3,668)               -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------
      Total                      24,579         4,269         2,744         2,806         3,165       (3,668)          33,895

(Loss) income from operations      (329)          647           294           674          (257)         (59)             970

</TABLE>


The Company's U.S. operation made net export sales to unaffiliated  customers of
approximately  $1,440,210 and $1,230,000 for the three months ended November 30,
2001 and 2000,  respectively  and  $2,746,210  and $2,896,000 for the six months
ended November 30, 2001 and 2000,  respectively.  The Company's German operation
made net export sales to unaffiliated  customers of  approximately  $813,660 and
$170,000 for the three months ended November 30, 2001 and 2000, respectively and
$1,015,078  and $387,000  for the six months  ended  November 30, 2001 and 2000,
respectively.  The  Company's  Canadian  operation  made  net  export  sales  to
unaffiliated  customers  of  approximately  $387,000  and $720,000 for the three
months  ended  November  30,  2001  and  2000,  respectively  and  $902,000  and
$1,280,000  for the six months ended  November 30, 2001 and 2000,  respectively.
Product sales to affiliates are valued at market prices.





<PAGE>



5.    COMPREHENSIVE INCOME (LOSS)

The components of comprehensive  income (loss) for the three-month and six-month
periods ended November 30, 2001 and 2000 are as follows:

<TABLE>
<CAPTION>
                                              Three Months Ended                         Six Months Ended
                                      November 30,         November 30,         November 30,           November 30,
                                          2001                 2000                 2001                   2000
                                     ----------------     ----------------    ------------------     -----------------

<S>                                   <C>                 <C>                  <C>                      <C>
Net income (loss)                     $  2,231,140        $    (612,249)       $  3,483,816             $  (827,680)

Net foreign currency translation          (157,309)            (243,931)            794,193                (998,973)

Cumulative effect of the adoption
of FAS 133 on June 1, 2001, net of
taxes                                            -                   -             (102,721)                    -
                                     ----------------     ----------------    ------------------      ----------------

Comprehensive income (loss)           $  2,073,831         $   (856,180)       $  4,175,288             $(1,826,653)
                                     ================     ================    ==================     =================
</TABLE>

Accumulated  comprehensive  loss as of  November  30,  2001 and May 31, 2001 was
($5,894,340) and ($6,585,812),  respectively.  The balance consists primarily of
net losses on foreign currency translation adjustments and has been disclosed in
the shareholders' equity section of the consolidated balance sheets.


6.   LOANS TO OFFICERS AND DIRECTORS

On June 6, 2000 Edward L. Gallup,  President  and CEO of Immucor,  Inc.  entered
into a loan  agreement  with Immucor,  Inc. to borrow up to $400,000 in order to
meet margin calls related to loans made by brokerage companies. The Company made
the loan because it believed that certain  benefits  would accrue to the Company
and its  shareholders  if such margin  calls were  satisfied by some means other
than having  those  shares sold by the broker.  The loan is payable on demand by
the Company  and bears  interest  at the rate  charged by the Company  under the
Company's  loan  agreement  with its principal  lender.  The amount of principal
outstanding  from Mr. Gallup on November 30, 2001 was $251,000,  and was secured
by 105,000 Immucor shares. The loan was repaid after November 30, 2001.


7.     IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS

Effective June 1, 2001, the Company  adopted  Statement of Financial  Accounting
Standards No. 133, Accounting for Derivative  Instruments and Hedging Activities
("Statement  133").  Statement  No. 133 requires  the Company to  recognize  all
derivatives on the balance sheet at fair value.  For  derivatives  designated as
hedges,  the change in the fair value of the  derivative  will  either be offset
against  the change in the fair value of the hedged  asset,  liability,  or firm
commitment  through earnings or recognized in other  comprehensive  income until
the  hedged  item is  recognized  in  earnings.  The  ineffective  portion  of a
derivative's change in fair value will be immediately recognized in earnings. As
of November 30, 2001, the Company had two interest rate swap agreements to hedge
against exposure to interest rate risk. The cumulative effect of the adoption of
FAS  133 on June 1,  2001  resulted  in a  comprehensive  loss of  approximately
$103,000, relating to the interest rate swap agreements. The ineffective portion
of the  derivative's  change in fair value  resulted  in a charge of $200,000 to
earnings for the quarter ended November 30, 2001.

In June 2001,  the  Financial  Accounting  Standards  Board issued  Statement of
Financial  Accounting  Standards No. 141,  Business  Combinations,  and No. 142,
Goodwill  and Other  Intangible  Assets,  collectively,  the  Statements.  These
Statements drastically change the accounting for business combinations, goodwill
and intangible assets. Statement 141 eliminates the pooling-of-interests  method
of  accounting  for  business   combinations   except  for  qualifying  business
combinations  that were  initiated  prior to July 1,  2001.  Statement  141 also
changes the criteria to recognize  intangible assets apart from goodwill.  Under
Statement 142,  goodwill and indefinite  lived  intangible  assets are no longer
amortized  but are  reviewed  annually for  impairment,  or more  frequently  if
impairment indicators arise.  Separable intangible assets that have finite lives
will  continue  to be  amortized  over  their  useful  lives.  The  amortization
provisions of Statement  142 apply to goodwill and  intangible  assets  acquired
after June 30, 2001.  With respect to goodwill and  intangible  assets  acquired
prior  to July  1,  2001,  the  amortization  provisions  of  Statement  142 are
effective upon adoption of Statement 142.  Pre-existing goodwill and intangibles
will be amortized  during the transition  period until  adoption.  Companies are
required to adopt  Statement 142 in their fiscal year  beginning  after December
15, 2001.  Early adoption is permitted for companies with fiscal years beginning
after March 15, 2001. The Company plans to adopt Statement 142 effective June 1,
2002.


8.       INCOME TAX (BENEFIT) EXPENSE

Income  tax  (benefit)  expense  as  shown  in the  statements  of  consolidated
operations differ from the amount that would be computed if income before income
taxes was  multiplied by the United States  federal  income tax rate  (statutory
rate) applicable in each period. The reasons for this difference are as follows:
<TABLE>
<CAPTION>

                                                   Three Months Ended                  Six Months Ended
                                             November 30,      November 30,     November 30,      November 30,
                                                 2001              2000             2001              2000

<S>                                            <C>              <C>             <C>               <C>
Benefit (expense) at statutory rate            $    959,862     $   (123,071)   $    1,461,914    $    (190,877)
Increase (decrease) resulting from:
   Amortization                                     138,280          150,845           276,935          315,436
   Net operating loss carry-forward                (590,068)               -        (1,153,244)               -
   Foreign operations                               177,581          315,621           389,645          487,891
   Other                                            (93,672)         (93,119)         (159,319)        (346,173)
                                           -----------------------------------------------------------------------
Tax provision per statement of operations      $    591,983     $    250,276    $      815,931     $    266,278
                                           =======================================================================
</TABLE>



9.       SUBSEQUENT EVENTS

On September 11, 2001 the Company successfully  completed  negotiations with its
primary  lender to issue a waiver  of  covenant  defaults  and to reset the loan
covenants for the next four quarters in the Loan  Agreement  dated  February 23,
2001.  The Company  will pay a waiver fee of $750,000  in twelve  equal  monthly
payments beginning September 30, 2001,except that the unpaid balance of this fee
must be paid  upon the  Company's  receipt  of the  junior  capital  investment,
discussed in the following  paragraph.  The interest rate on the revolving lines
of credit  and Term  Loan A were  reset to the  prime  rate  plus  0.50% and the
interest  rate on Term Loan B were  reset to the  prime  rate  plus  2.00%.  The
Company is  required  to meet  quarterly  and  cumulative  EBITDA  covenants  in
addition to quarterly funded debt to EBITDA ratios.  Once the Company's trailing
twelve-month  funded debt to EBITDA reaches 2.50 to 1 or less the interest rates
on these loans will revert back to the more  favorable  pricing  provided in the
Loan Agreement dated February 23, 2001.

An additional  requirement of the waiver is that the Company obtain a minimum of
$5.0 million in junior  capital,  in the form of either  equity or  subordinated
debt. Since the Company did not receive the investment by December 31, 2001, the
Company  must pay the lender an  additional  fee of  $450,000  payable in twelve
equal monthly  installments  beginning  January 31, 2002.  The Company will also
issue the lender a warrant to purchase 750,000 shares of Immucor,  Inc. stock at
the market price of the stock on December 31, 2001.  If the Company meets all of
its  quarterly  EBITDA  covenants  and no  other  events  of  default  are  then
occurring,  the number of shares the lender may purchase  under the warrant will
be reduced based on when the Company  raises the junior  capital.  Specifically,
the lender's  warrant would be reduced by 562,500  shares if the $5.0 million of
junior  capital is raised by January 31,  2002;  the lender's  warrant  would be
reduced by  375,000  shares if the $5.0  million of junior  capital is raised by
February 28, 2002;  and the lender's  warrant would be reduced by 187,500 shares
if the $5.0 million of junior capital is raised by March 31, 2002. Additionally,
since the junior  capital  investment was not received by December 31, 2001, the
revolving  lines of credit and Term Note A were re-priced at prime plus 2.0% and
Term Note B was  re-priced  at prime  plus  4.0%  until the  junior  capital  is
received.  If the junior capital is not received by April 30, 2002, all existing
credit facilities will be reset to mature on February 28, 2003.

Prior to December  31,  2001,  the Company had a signed  letter of intent with a
junior capital  investment group. Due to the upward movement of the market value
of the  Company's  stock after  signing this letter of intent,  it was no longer
attractive to the Company to obtain an  investment  from such group on the terms
provided for in the letter,  and the Company's  obligations under such letter of
intent have since expired (other than certain confidentiality requirements). The
Company has undertaken the search for a new junior capital  investment  partner.
Management  is  optimistic  that it can obtain  the  junior  capital in order to
satisfy that provision of the loan agreement. However, there can be no assurance
that the Company will be successful in obtaining  junior capital  financing,  or
that  the  Company  will be able to do so in  time  to  avoid  the  consequences
specified in its loan agreement with its principal lender.
<PAGE>

On December 3, 2001 the Company issued 521,500 stock options available under the
three Company stock option plans.

As part of the acquisition of Dominion  Biologicals  Limited, the Company issued
to the  sellers  five and ten year  warrants  to  acquire,  in whole or in part,
478,417  and  150,000  shares of  Immucor  stock at $12.00 and $11.98 per share,
respectively.  These  warrants  became  exercisable  one year after the issuance
date,  with the  five-year  warrants  expiring in December 2001 and the ten-year
warrants expiring in 2006.  Effective  December 11, 2001, the five-year warrants
have expired.

On June 6, 2000 Edward L. Gallup,  President  and CEO of Immucor,  Inc.  entered
into a loan  agreement  with Immucor,  Inc. to borrow up to $400,000 in order to
meet margin calls related to loans made by brokerage companies. The Company made
the loan because it believed that certain  benefits  would accrue to the Company
and its  shareholders  if such margin  calls were  satisfied by some means other
than having  those  shares sold by the broker.  The loan is payable on demand by
the Company  and bears  interest  at the rate  charged by the Company  under the
Company's  loan  agreement  with its principal  lender.  The amount of principal
outstanding  from Mr. Gallup on November 30, 2001 was $251,000,  and was secured
by 105,000 Immucor shares. The loan was repaid after November 30, 2001.


ITEM 2. Management's  Discussion and Analysis of Financial Condition and Results
of Operations.

    Any statements  contained  herein that are not statements of historical fact
are forward-looking statements as that term is defined in the Private Securities
Reform Act of 1995,  including,  without limitation,  statements  concerning the
Company's expectations,  beliefs, intentions or strategies regarding the future.
All  forward-looking  statements  included  in  this  discussion  are  based  on
information available to the Company on the date hereof, and the Company assumes
no obligation to update any such forward-looking  statements.  It is not certain
that the  Company  will  achieve  expected  sales and  earnings,  which could be
adversely  affected  by  a  variety  of  factors,  including  significant  price
decreases by our  competitors  and the  strengthening  of the dollar  versus the
Euro.  In addition,  continued  weakness in the economy and other  factors could
cause  customers  to  defer  capital  spending,  which  would  adversely  impact
instrument sales.


Financial Condition and Liquidity:

As of November 30, 2001,  the  Company's  cash  position  totaled $3.6  million.
Accounts receivable increased by $3.6 million due to the reagent price increases
that had a significant  impact on the second quarter and could further  increase
as the receivable  cycle is completed.  Prepaid  expenses and other increased by
$1.4  million due to $0.6  million due from  Becton,  Dickinson,  not later than
April  1,  2002  and due to  deferred  costs  for  instruments  that  are in the
installation process.

Accounts payable  increased by $1.5 million as the Company  conserved  operating
cash-flows to meet scheduled  debt  payments.  Debt payments of $2.6 million and
capital  expenditures  of $1.2 million  related to the  enterprise  software and
instruments at customer sites on reagent rental  agreements were made during the
quarter.  Debt payments of $4.9 million and capital expenditures of $1.8 million
were made during the fiscal year.  Additional debt payments of $1.3 million were
made early in the third quarter from  operating  cash-flows.  Retained  earnings
(comprehensive  loss)  improved  by $3.5  million  due to the  earnings  for the
quarter  and total  shareholders'  equity  improved  by $4.2  million due to the
earnings for the quarter and by improvement in the foreign exchange translation.
See footnote 5.

On September 11, 2001 the Company successfully  completed  negotiations with its
primary  lender to issue a waiver  of  covenant  defaults  and to reset the loan
covenants for the next four quarters in the Loan  Agreement  dated  February 23,
2001.  The Company  will pay a waiver fee of $750,000  in twelve  equal  monthly
payments  beginning  September 30, 2001,  except that the unpaid balance of this
fee must be paid upon the Company's  receipt of the junior  capital  investment,
discussed in the following  paragraph.  The interest rate on the revolving lines
of credit and Term Loan A were  reset to prime rate plus 0.50% and the  interest
rate on Term Loan B were  reset to the prime  rate plus  2.00%.  The  Company is
required  to meet  quarterly  and  cumulative  EBITDA  covenants  in addition to
quarterly funded debt to EBITDA ratios. Once the Company's trailing twelve-month
funded  debt to EBITDA  reaches  2.50 to 1 or less the  interest  rates on these
loans  will  revert  back to the more  favorable  pricing  provided  in the Loan
Agreement dated February 23, 2001.
<PAGE>

An additional  requirement of the waiver is that the Company obtain a minimum of
$5.0 million in junior  capital,  in the form of either  equity or  subordinated
debt. Since the Company did not receive the investment by December 31, 2001, the
Company  must pay the lender an  additional  fee of  $450,000  payable in twelve
equal monthly  installments  beginning  January 31, 2002.  The Company will also
issue the lender a warrant to purchase 750,000 shares of Immucor,  Inc. stock at
the market price of the stock on December 31, 2001.  If the Company meets all of
its  quarterly  EBITDA  covenants  and no  other  events  of  default  are  then
occurring,  the number of shares the lender may purchase  under the warrant will
be reduced based on when the Company  raises the junior  capital.  Specifically,
the lender's  warrant would be reduced by 562,500  shares if the $5.0 million of
junior  capital is raised by January 31,  2002;  the lender's  warrant  would be
reduced by  375,000  shares if the $5.0  million of junior  capital is raised by
February 28, 2002;  and the lender's  warrant would be reduced by 187,500 shares
if the $5.0 million of junior capital is raised by March 31, 2002. Additionally,
since the junior  capital  investment was not received by December 31, 2001, the
revolving  lines of credit and Term Note A were re-priced at prime plus 2.0% and
Term Note B was  re-priced  at prime  plus  4.0%  until the  junior  capital  is
received.  If the junior capital is not received by April 30, 2002, all existing
credit facilities will be reset to mature on February 28, 2003.

Prior to December  31,  2001,  the Company had a signed  letter of intent with a
junior capital  investment group. Due to the upward movement of the market value
of the  Company's  stock after  signing this letter of intent,  it was no longer
attractive to the Company to obtain an  investment  from such group on the terms
provided for in the letter,  and the Company's  obligations under such letter of
intent have since expired (other than certain confidentiality requirements). The
Company has undertaken the search for a new junior capital  investment  partner.
Management  is  optimistic  that it can obtain  the  junior  capital in order to
satisfy that provision of the loan agreement. However, there can be no assurance
that the Company will be successful  in obtaining  junior  capital  financing or
that the  Company  will be able to do so in time to avoid  the  consequences  as
specified in its loan agreement with its principal lender.

Management  expects  that  with the  aggressive  price  increase,  cash and cash
equivalents  and  internally  generated  funds  will be  sufficient  to  support
operations and planned capital expenditures for the next 12 months. In addition,
Management believes that most capital expenditure planned for the next 12 months
can be delayed in the event capital resources become inadequate.


Results of Operations:

During the quarter  the Company  improved  net income by $2.8  million  over the
prior year. For the six-month  period,  the Company  improved net income by $4.3
million over the prior year and received $1.2 million from the  settlement  with
Becton,  Dickinson and Company.  The  implementation of the cost savings plan in
the fourth  quarter of fiscal  2001 has had a positive  effect on the  Company's
cash  position.  The net result of the  quarter's  cash-flow  was a $.7  million
improvement in cash position compared to the prior year.

Net sales

Revenues for the quarter  ended  November 30, 2001 rose by $4.1 million over the
same quarter last fiscal year largely due to the aggressive price increase begun
in the third  quarter of fiscal  year 2001 and new group  contracts.  Instrument
sales for the quarter ended  November 30, 2001 were up slightly to $0.7 million,
although there remains a backlog over $1 million.  As a result of the lifting of
the ABS2000  safety alert,  the Company  expects  instrument  sales to return to
previous levels.  For the first six months of the year revenues totaled a record
$39.6 million, a $5.67 million,  or 16.7%,  increase over the prior year period.
Reagent price increases  contributed  approximately $5.3 million to the increase
for the year.

The Company expects to improve sales by $12.0 million for the fiscal year ending
May 31, 2002 as a result of the price increases and a single new group contract.
This  estimate is based on,  among  other  things,  the fact that a  substantial
portion of the fiscal  year is  complete  and the  amount of order  backlog  and
contractually  committed  purchases.  In making  this  projection,  the  Company
extrapolated recent past results and assumed existing customers will continue to
make  purchases at their  current rate of purchase at current  prices.  Further,
Immucor has assumed that it will not lose any  customers or gain any  customers,
or that  revenues  from new  customers  will  offset  lost  revenues  from  lost
customers. Offsetting the reagent price increases and new group contracts is the
loss of sales of ReACT due to patent  infringement issues and the de-emphasis of
sales of low margin OEM products.  The Company has also assumed that  instrument
sales will be consistent with, and not improve over the previous fiscal year.
<PAGE>

Investors are cautioned  against  attributing  undue  certainty to the Company's
assessment  of the future since there can be no assurance  that the Company will
achieve  this level of revenues.  Immucor's  ability to do so could be adversely
affected  by a  variety  of  factors,  the most  significant  of  which,  in the
Company's  opinion,  are  significant  price decreases by our  competitors,  the
general  condition of the economy (which could  deteriorate to such a point that
it causes  customers to defer  capital  spending  which would  adversely  impact
instrument sales),  unexpected expenses and increased  regulatory costs, and the
value of the Euro versus the Dollar,  which would depress the Company's European
results  if the  Euro  were  to  decline.  Additionally,  the  Company  has  not
determined what effect,  if any, the  stockpiling of Immucor's  products by some
customers prior to such customers'  price increases will have on the reliability
of Immucor's  projections.  Investors  are also  cautioned  that Immucor has not
determined whether it will issue projections in the future or update its current
projection if not otherwise required to do so by the federal securities laws.

Gross profit

Gross profit  increased $3.9 million as compared to the prior year's quarter and
increased $4.6 million  compared to the prior year to date due to the aggressive
price increases  mentioned above. In addition,  the Company avoided  significant
costs incurred in prior periods to resolve the ABS2000 issue and related product
concessions provided to customers who were required to perform backup testing.


Operating expenses

When  compared  to the prior  year,  research  and  development  costs  remained
relatively constant, primarily related to instrument development initiatives for
the Galileo for the European market. The Galileo is designed to fulfill the need
in Europe for a high-throughput blood  serology-testing  device with a test menu
that includes  antibody  screening.  The Company is beginning trials outside the
United  States to be staged  for full  European  market  launch in the spring of
2002.

Selling and marketing expenses decreased $0.24 million for the quarter and $0.94
million for the year to date,  as  compared to the same period last year.  Until
the  fourth  quarter  of  fiscal  2001,  the  Company  had  been  developing  an
infrastructure  to support an increased level of instrument  sales. But in light
of the issues with the ABS2000 and  continued  customer  migration to purchasing
groups,  the Company  reevaluated the focus of the sales and marketing  efforts.
The domestic and Netherlands sales staff was significantly  reduced resulting in
a positive  effect on the first and second quarter net income.  In addition,  in
the prior year, the Company recorded  $160,000 in additional  expense related to
the ABS2000 problems.

Distribution  expenses for the quarter and year to date ended  November 30, 2001
remained  relatively constant as compared to the prior year, but as a percentage
of sales,  have decreased from 8.4% to 7.3%.  Any additional  shipping  expenses
related to the new purchasing  group was offset by volume  discounts  offered by
carriers.

General and  administrative  expenses for the quarter and six-month period ended
November 30, 2001 increased $0.76 million and $0.89 million,  respectively,  due
primarily to legal  expenses  related to the proxy  contest and various bank and
professional fees.  Amortization  expense remained  relatively constant with the
prior period.

Interest expense

When  compared to the prior year  three-month  and  six-month  period,  interest
expense  increased  $0.6  million and $0.9  million,  respectively.  This is the
result of the increased  borrowings on long-term  debt, bank fees related to the
Company's  inability to maintain the financial  covenants contained in its prior
loan agreement due to past operating  losses,  and capitalized  leases in fiscal
2001.

Other income

Interest  income  declined  due to  fewer  funds  available  for  investment  in
interest-bearing  accounts.  Other income for the second  quarter was  favorably
affected by the disgorgement of short-swing  trading profits by the Kairos Group
that  contributed  $0.36 million to pre-tax  income.  Other income for the first
quarter of fiscal 2002 was favorably  affected by the  settlement of the Becton,
Dickinson  arbitration.  The settlement called for Becton to pay Immucor, Inc. a
total of $1.8 million,  payable in two  installments.  The first payment of $1.2
million was made on June 11, 2001,  with the second  installment of $0.6 million
payable  not later than  April 1, 2002.  Assets of  approximately  $1.0  million
related to IMAGN were written off with the transaction. These items of income do
not arise from the Company's ongoing business.
<PAGE>

Income taxes

Income tax expense increased during the three-month  period and six-month period
ended November 30, 2001, as compared to the prior period,  due to higher income.
Income tax expense continues to be lowered by Net Operating Loss  Carry-forwards
generated in fiscal 2001 that reduce the current  United  States tax  provision.
During  the fourth  quarter  of fiscal  2001,  the  Company  elected to record a
valuation  allowance  in an amount  equal to the net  deferred tax assets of the
Company,  amounting  to  $1.2  million.  Effectively,  this  non-cash  allowance
reflected the  elimination  of domestic  deferred taxes as a balance sheet asset
and  will be used to  reduce  domestic  taxes in the  current  year now that the
Company has returned to profitability.



ITEM 3.  Quantitative and Qualitative Disclosures On Market Risk

There have been no material changes regarding the Company's market risk position
from the  information  provided in its Annual Report on Form 10-K for the fiscal
year ended May 31, 2001. The  quantitative  and  qualitative  disclosures  about
market risk are discussed in Item  7A-Quantitative  and Qualitative  Disclosures
About Market Risk, contained in the Company's Form 10-K.



                                     PART II

                                OTHER INFORMATION


ITEM 4.  Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Shareholders on November 30, 2001.  Ralph
A. Eatz, Edward L. Gallup,  Gioacchino De Chirico,  Didier L. Lanson,  Daniel T.
McKeithan, and Joseph E. Rosen were re-elected as directors of the Company.

The following is a summary of the matters voted on at that meeting.

(a)    The shareholders voted on the election of six (6) directors,  each
       to serve for a one-year  term.  The number of shares  cast for and
       the  number  of shares  withheld,  with  respect  to each of these
       persons, were as follows:

       ------------------------------- -------------------- -------------------
                     Name                     Votes For       Votes Withheld
       ------------------------------- -------------------- -------------------
       Ralph A. Eatz                          3,831,136           69,665
       ------------------------------- -------------------- -------------------
       Edward L. Gallup                       3,823,084           77,717
       ------------------------------- -------------------- -------------------
       Gioacchino De Chirico                  3,831,136           69,665
       ------------------------------- -------------------- -------------------
       Didier L. Lanson                       3,829,536           71,265
       ------------------------------- -------------------- -------------------
       Daniel T. McKeithan                    3,830,214           70,587
       ------------------------------- -------------------- -------------------
       Joseph E. Rosen                        3,830,054           70,747
       ------------------------------- -------------------- -------------------
       John F. McGuire, III                   1,066,842           36,305
       ------------------------------- -------------------- -------------------
       Ronald O. Gilcher, M.D.                1,064,498           38,649
       ------------------------------- -------------------- -------------------
       Pierre G. Cassigneul                   1,064,488           38,659
       ------------------------------- -------------------- -------------------
       Peter R. White                         1,064,488           38,659
       ------------------------------- -------------------- -------------------



(b)           The shareholders  voted on the right to adjourn the Annual Meeting
              if the Board of Directors  determined  that Immucor needed time to
              solicit more votes to elect the nominees  recommended by the Board
              of Directors of Immucor,  and to oppose any attempt to adjourn the
              meeting if the  proposal to adjourn was made in order to allow any
              other  person time to solicit more votes to elect  nominees  other
              than those  recommended by the Board of Directors of Immucor.  The
              number of shares cast for and the number of shares withheld,  with
              respect to this matter, were as follows:

        --------------------------------- ----------------------------
        Votes For                                  3,823,084
        --------------------------------- ----------------------------
        Votes Withheld                              77,717
        --------------------------------- ----------------------------



<PAGE>



Item 5.  Other

Two members of the board of directors  resigned  during the  quarter.  Dennis M.
Smith,  Jr.,  M.D.  resigned as a director on September  18, 2001,  and G. Bruce
Papesh  resigned as a director on October 1, 2001.  On October 1, 2001 the Board
of  Directors  unanimously  approved a  resolution  that reduced the size of the
Board of Directors to six members so as to eliminate  the vacancies on the board
created by these two resignations.  On December 19, 2001, the Board of Directors
unanimously  approved  a  resolution  that  increased  the size of the  Board of
Directors  to seven  members  and  appointed  Roswell S.  Bowers to the Board of
Directors.  The  changes  in the size of the  board had the  affect of  amending
Section 3.2 of the Company's bylaws.

On November  20,  2001,  the Board of  Directors  approved an  amendment  to the
Company's  shareholder rights agreement (the "Rights Plan"). The modification to
the Rights Plan  eliminated  the  continuing  director or  so-called  "deadhand"
provisions of the Rights Plan.  Previously,  these provisions  prevented certain
changes to the rights plan or the rights,  including the termination of the plan
or the  redemption  of the  rights,  without  the  approval of a majority of the
directors  in  office  prior to the time the  rights  are  triggered.  All other
provisions of the Rights Plan were unaffected by the amendment.

On November 30, 2001 the board of directors approved indemnification  agreements
between the Company and each of Ralph A. Eatz,  Edward L. Gallup,  Gioacchino De
Chirico,  Didier L. Lanson,  Daniel T.  McKeithan,  Joseph E. Rosen and G. Bruce
Papesh.  A form of such  agreement  is filed as an exhibit to this  report.  The
agreement  obligates  the Company to  indemnify  these  directors to the fullest
extent permitted by applicable law and advance certain expenses incurred by them
as a result of being  involved  in certain  legal  proceedings  in their role as
directors of the Company.

Item 6.  Exhibits and Reports on Form 8-K.

(a)      The Company has filed the following exhibits with this report:

3.1      Amended  and  Restated  Articles  of  Incorporation   (incorporated  by
         reference to Exhibit 3.1 to Immucor,  Inc.'s  quarterly  report on Form
         10-Q filed on January 16, 2001).

3.2      Amended and Restated Bylaws (amended  and  restated as  of December 19,
         2001).

4.1      Amended and Restated  Shareholder Rights Agreement dated as of November
         20, 2001 between   Immucor,  Inc.  and Equiserve  Trust  Company,  N.A.
         as Rights Agent.

10.21    Loan Modification No. 1 dated as of September 11, 2001 between Immucor,
         Inc., Dominion Biologicals  Limited,  Immucor  Medizinische  Diagnostik
         GmbH and Wachovia Bank, National Association.

10.22    Form  of  indemnification  agreement  between the Company  and  certain
         directors.

(b)      The  Company  did  not  file any  reports on Form  8-K during the three
         months ended November 30, 2001.



<PAGE>


                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                  IMMUCOR, INC.
                                  (Registrant)



Date: January 14, 2002








_/s/ Edward L. Gallup______    Edward L. Gallup, President
                               (Principal Executive Officer)







_/s/ Steven C. Ramsey_____     Steven C. Ramsey, Senior Vice President - Finance
                               (Principal Accounting Officer)



<PAGE>



EXHIBIT INDEX


Number                                      Description

3.1      Amended  and  Restated  Articles  of  Incorporation   (incorporated  by
         reference to Exhibit 3.1 to Immucor,  Inc.'s  quarterly  report on Form
         10-Q filed on January 16, 2001).

3.2      Amended and Restated Bylaws (amended and  restated  as of  December 19,
         2001).

4.1      Amended and Restated Shareholder Rights Agreement  dated as of November
         20, 2001  between Immucor, Inc. and  Equiserve  Trust Company,  N.A. as
         Rights Agent.

10.21    Loan   Modification  No. 1 dated  as  of  September  11,  2001  between
         Immucor,  Inc.,   Dominion  Biologicals  Limited, Immucor  Medizinische
         Diagnostik GmbH and Wachovia Bank, National Association.

10.22    Form of  indemnification  agreement  between  the  Company and  certain
         directors.